Seaport Therapeutics, Inc. (NASDAQ:SPTX – Get Free Report) Director Robert Hombach purchased 13,000 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average price of $18.14 per share, with a total value of $235,820.00. Following the acquisition, the director directly owned 13,000 shares of the company’s stock, valued at $235,820. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
Seaport Therapeutics Stock Performance
Shares of NASDAQ:SPTX opened at $21.40 on Friday. Seaport Therapeutics, Inc. has a 52-week low of $14.85 and a 52-week high of $23.00.
Seaport Therapeutics (NASDAQ:SPTX – Get Free Report) last issued its earnings results on Monday, June 8th. The company reported ($10.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($10.64) by $0.30.
Analyst Ratings Changes
View Our Latest Analysis on SPTX
See Also
- Five stocks we like better than Seaport Therapeutics
- Rocket Lab’s NASA Win Tests Key Support After Sharp Pullback
- AST SpaceMobile Just Nailed a Major Launch—So Why Is the Stock Crashing?
- Palantir’s Valuation Problem Just Met 2 New Growth Catalysts
- Xcel Energy Stock Offers Stability as Electricity Demand Builds
Receive News & Ratings for Seaport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seaport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
